Nine Percent Organic Proves the Recovery; a Tariff-Funded Beat and a Vascular Hole Explain the Selloff

Results vs. Consensus

Q2 2026 Scorecard

The adjusted EPS consensus of $3.49 is unanimous across the three reads we cross-checked. The revenue consensus carries a narrow spread of $6.57B to $6.58B; on any anchor inside that range the revenue line is a rounding error rather than a beat, and the characterization does not change. Quarterly free cash flow is derived by subtracting the first quarter from the reported six-month statement, so both endpoints are filed figures.

Year-Over-Year Comparison

First-Half Comparison

The six-month column is where the year's arithmetic actually lives, because everything the guide now requires is expressed against it.

Quarter-Over-Quarter Comparison

Last quarter this table showed a 910 bp sequential collapse in adjusted operating margin, of which roughly 280 bps was the excess over the ordinary Q4-to-Q1 seasonal step-down and therefore the cleanest available measurement of what three dark weeks cost the P&L. This quarter it recovers 630 bps of that in one step. The sequential top line is normally diagnostically useless at Stryker because of the pronounced fourth-quarter skew, but Q1 to Q2 is the one sequential comparison that carries information this year: it is the recovery, measured.

Revenue

Net sales of $6,589M grew 9.4% as reported, 9.0% in constant currency and 9.0% organic, with foreign exchange contributing 0.4 points and acquisitions and divestitures netting to zero for the first time in two years. Pricing was flat. Every point of growth was volume, and it came against a Q2 2025 that itself grew 10.2% organic, so the two-year stack is roughly 19 points.

"Organic sales growth was 9% for the quarter, against a double digit comparable in the second quarter of 25. Pricing was flat, and foreign currency had a 0.4% favorable impact on sales."
— Preston Wells, CFO

Two things about that 9.0% matter more than the number itself. The first is that it is understated. A supply failure at a single Inari plant drove U.S. Vascular organic down 6.7%, which on the prior-year U.S. Vascular base of $268M, against a counterfactual in which it had grown at the company rate of roughly 8%, implies about $39M of lost revenue, or about 65 bps of company organic growth. Adjusting for it, the clean run-rate is closer to 9.6%. The second is that the acquisition and divestiture line finally netted to zero: the spinal implants exit is exhausted, with Spinal Implants revenue down to $3M from $5M, and Inari has anniversaried out of the acquisition column. Reported and organic growth converge from here, which makes 2027 the first genuinely clean comparison base in three years.

Assessment: This is what the recovery was supposed to look like at this stage and it is neither better nor worse than that. Nine percent organic on a ten percent comparable, all volume, with the two structural distortions of the last two years both finished, is a franchise operating normally. The disappointment in the market's reaction is not about this quarter's growth rate; it is about what the guide implies has to happen next.

Margins

Adjusted gross margin of 66.0% expanded 60 bps and adjusted operating margin of 27.4% expanded 170 bps, the largest expansion in either metric in the last eight quarters. The operating-margin bridge is clean and it is mostly not gross margin: 60 bps from gross margin, 90 bps from adjusted SG&A falling to 32.2% of sales, and 20 bps from adjusted R&D at 6.4%. The SG&A leverage is the honest part of this print, and it is the same discipline that held the ratio flat in a first quarter when the revenue base disappeared underneath it.

The gross margin line is the part that needs an asterisk, and management supplied it unprompted.

"Our adjusted gross margin of 66% was 60 basis points favorable to the second quarter of 25. Reflecting the impact of the net tariff benefit I previously mentioned as well as improvements in business mix and cost discipline."
— Preston Wells, CFO

The tariff benefit is named first among three drivers and is quantified nowhere: not in the release, not in the reconciliation, not on the call. It is separate from, and additional to, the $158M "reversal of 2025 tariffs" that appears in the reconciliation as a negative adjustment and is therefore excluded from every adjusted figure above. That excluded item is why reported cost of sales fell 4.1% on sales up 9.4%, and why reported gross margin of 68.3% sits above adjusted gross margin of 66.0%, which is the inverse of the normal relationship and worth flagging to anyone screening on GAAP margins this quarter.

Assessment: Strip an unsized tariff tailwind out of 60 bps of gross margin expansion and the honest range for underlying gross margin performance runs from modestly positive to flat. The 170 bps of operating margin expansion survives that treatment better than the headline suggests, because 110 of the 170 bps came from operating expense leverage that has nothing to do with trade policy. But the first half now sits 50 bps below last year's on gross margin, and for full-year adjusted gross margin to match 2025's 65.3% the second half has to run roughly 60 bps above the second half of 2025, which is to say roughly what this quarter just delivered with the tariff benefit included.

Earnings

Adjusted EPS of $3.69 grew 17.9%, the strongest growth rate since the Inari integration began, and adjusted net earnings of $1,424M grew 17.6% on a diluted share count that was essentially flat at 386.0M. The divergence between reported EPS growth of 44.1% and adjusted growth of 17.9% is almost entirely a base effect rather than an achievement: Q2 2025 carried $432M of pre-tax adjustments including $65M of Inari inventory step-up, $78M of other acquisition and integration costs and $55M of impairments, against a net $148M this quarter after the $158M tariff reversal is netted against $306M of ordinary charges.

The adjusted effective tax rate of 16.5% ran 60 bps above the prior year and above the top of the 15% to 16% full-year range the company reiterated, which makes the tax line a small headwind inside the quarter rather than a contributor to it. Free cash flow of $1,059M grew 14.1%, and on a six-month basis operating cash flow of $1,842M was 35.3% ahead of last year with free cash flow up 39.7%. First-half conversion on adjusted net earnings of 60.7% is well ahead of last year's 45.7% and consistent with a business whose cash generation is structurally weighted to the second half.

Assessment: The earnings quality is good in every dimension except the one that matters most this quarter. Nothing is propped up by tax, share count or below-the-line items, cash conversion is genuinely improving, and the operating leverage is visible in the expense ratios. What cannot be verified is how much of the operating income growth is a trade-policy windfall that reverses. Management had the opportunity to size it three separate times and did not.

Segment Performance

The Ortho Tech recast that took effect in the first quarter is now on both sides of every comparison below, so year-over-year figures within these tables are like-for-like. Comparisons against business-line figures published before the first quarter of 2026 are not.

Reportable Segments

Business Lines

Percentages are as disclosed and are computed on unrounded figures, so several business-line growth rates do not recompute exactly from the rounded dollar columns beside them. The U.S. organic column is management's disclosure on the call and is a different measure from the two columns to its left, which are total-business reported and constant-currency rates.

Geographic Mix

MedSurg and Neurotechnology: the capital engine restarts

Organic growth of 9.2% is a swing of 830 bps from the first quarter's 0.9%, and it is concentrated exactly where the outage did its damage. Medical grew 13.4% reported with U.S. organic growth of 13.1%, led by the Sage skin-prep portfolio, emergency care and continued share capture from the LIFEPAK 35 defibrillator. Endoscopy grew 11.7% with U.S. organic growth of 10.2%, driven by operating-room infrastructure and renovation projects, urology, connected-OR products and double-digit sports medicine growth on an expanded shoulder implant range. Instruments grew 9.3% with U.S. organic growth of 8.4% against a prior-year comparable of 16.3%, on interventional spine pain and the Surgical Technologies portfolio.

The most interesting disclosure in this segment was a negative one delivered as an aside. Asked to separate underlying growth from catch-up, the CEO volunteered that the hospital-bed business inside Medical was a drag on a segment that grew double digits, because bed production cannot be caught up quickly.

"But overall, we hit the number that we were aiming for. In the quarter, because we had some out performances in endoscopy and medical and even within medical, our bed business we have tremendous number of orders that we have a big job to catch up to deliver."
— Kevin A. Lobo, Chair and CEO

Assessment: This is the segment carrying the second-half catch-up, and this quarter it delivered its recovery while still holding back the hardest bucket. The bed backlog is unrecognized revenue with a purchase order behind it, which is the most legible kind of forward revenue there is, and it is sitting in the second half by production constraint rather than by demand. That is the single most encouraging detail in the print.

Orthopaedics: normalized, and the drag finally exhausted

Organic growth of 8.6% with U.S. organic at 9.1% is the segment operating at trend. Trauma and Extremities led at 11.9% reported and 12.5% U.S. organic on Pangaea plating and a shoulder franchise now carrying Mako Shoulder on the Mako 4 platform. Ortho Tech grew 10.3% on robust Mako installations, which is the first quarter in which the robotics revenue line is visible in a business unit of its own with a clean comparative. Knees grew 8.4% reported and 6.2% U.S. organic on continued Mako adoption and cementless momentum.

Hips was the soft line at 2.9% reported and 4.9% U.S. organic, and it drew the only direct competitive question of the call. Management pushed back on the share-shift reading and pointed at the comparable.

"Travis, in terms of U.S. hips, nothing that we would point to in terms of major share shifts or changes there. I think the 1 thing I would point out is, again, the delivery of the number this year was against a pretty large prior year comparable. So we had 8% growth last year in that space."
— Preston Wells, CFO

Assessment: Hips at 4.9% U.S. organic against a high-single-digit comparable is unremarkable in isolation and would not merit attention except that hips is the franchise where competitive robotics offerings have narrowed the gap most visibly. One quarter is not a trend, as management said, but this is the line to watch in October, because it is the one place where the bear argument about a structurally narrowing orthopaedic moat could show up in the numbers before it shows up in the narrative.

Vascular: the quarter's self-inflicted wound

Total Vascular revenue of $496M fell 0.7% reported and 1.8% in constant currency, with U.S. organic down 6.7%. The cause was not demand and not competition; it was a supply failure at a single Inari manufacturing plant that produces most of the business's own products.

"This growth was offset by supply disruptions in our peripheral vascular business. While our sales force hiring and integration has made great progress, the supply disruption resulted in a meaningful backorder situation with lost sales in the quarter."
— Kevin A. Lobo, Chair and CEO

The offsetting strength inside the segment was the hemorrhagic portfolio, driven by the SURPASS Elite flow diverter, which is a reminder that Vascular is two businesses and only one of them broke. Management said backorders will reach a manageable level by the end of the third quarter, expects the business to grow in both remaining quarters, and declined to describe what actually failed.

Assessment: The revenue is small and largely recoverable; the signal is not. Inari was acquired in early 2025 in the largest cash outlay Stryker has made in years, and the first year was consumed by sales-force turnover and non-compete disputes. Year two opens with a manufacturing failure in the plant that makes most of the products. The bull case for paying that price was that Stryker's commercial and operational machine would improve the asset. Two consecutive years of self-inflicted disruption is evidence in the other direction, and it lands directly on the capital-allocation pillar of our thesis rather than on the recovery story.

International: the quiet outperformance

International revenue of $1,630M grew 11.0% reported, 9.2% in constant currency and 8.9% organic, essentially matching the U.S. rate for the first time in several quarters. Growth was led by Australia and New Zealand, Germany, Canada, South Korea, Japan, India and Brazil. Management repeated the first quarter's observation that the conflict in Iran had a modest impact on overall company growth, and repeated the slight European procedural softness flagged in April, which by their own account has not spread.

Assessment: The international line has become a genuine second growth engine rather than a currency artifact, and the mechanism management describes is unglamorous and credible: introducing products that already succeeded in the United States into markets that have not had them. That is a multi-year runway that costs very little incremental research spending, and it is under-discussed relative to its contribution.

Key Topics & Management Commentary

Overall Management Tone: Confident and noticeably less defensive than in April, with the posture of a team that believes the hard part is behind it. The tone shift is most visible in what management now volunteers: the CEO raised the lower guidance bound unprompted as evidence of confidence, and the CFO disclosed a returning share repurchase program without being asked. Where management remained unconvincing was on quantification, which was declined on the tariff benefit, the cyber remediation cost, the recovery-bucket split and the nature of the vascular plant failure, a pattern now consistent across two consecutive calls.

1. The Beat That Did Not Reach the Guide

The single most important exchange of the call was the first one, and it framed everything after it. Adjusted EPS beat by $0.20 and the full-year midpoint moved from $15.00 to $15.025. The CFO's explanation has two halves, and both are material.

"So from an EPS standpoint, when we look at the beat in the quarter, it is driven partially by the tariff refunds that are happening that happened in the quarter."
— Preston Wells, CFO

That is the first half: some of the beat was never operating earnings. The second half is why none of the rest survives to the full year.

"There are costs that are coming through from a cyber perspective, both with loss absorption from manufacturing as well as R&D or our IT costs"
— Preston Wells, CFO

Assessment: This is a fair and even admirable answer, and it is also the reason the stock fell. Management is telling investors that the underlying earnings power of 2026 did not improve this quarter: a policy windfall arrived early and a remediation bill arrives later, and they roughly cancel. Anyone who modelled the $0.20 through to the year was modelling something management never claimed.

2. Two Tariff Effects, and Only One of Them Is Disclosed

The reconciliation contains a line item labelled reversal of 2025 tariffs, worth $158M of gross profit and operating income, $133M of net earnings and $0.34 of diluted EPS, entered as a negative adjustment and therefore fully excluded from adjusted results. That is the disclosed effect, and management handled it correctly by taking it out. It is also why reported cost of sales fell in absolute dollars on a 9.4% sales increase.

The undisclosed effect is the one inside adjusted results. It appears three times in management's own language, first in the prepared remarks as a driver of the adjusted EPS growth rate.

"Driven by our strong sales growth a continued focus on operational excellence and a net benefit in the quarter from tariff related costs."
— Preston Wells, CFO

Then as the first-named driver of gross margin expansion, and then in Q&A as a driver of the beat. No figure is attached at any point.

Assessment: A company that goes to the trouble of separately disclosing a $158M prior-year tariff reversal and excluding it from adjusted results, while leaving an unquantified current-year tariff benefit inside adjusted results, has drawn a line that flatters the adjusted number. We are not alleging anything improper. We are saying that the 60 bps of adjusted gross margin expansion cannot be attributed between policy and performance from the outside, and that a single sentence with a number in it would have resolved it.

3. What the Narrowed Guide Actually Requires

The organic guide narrowed from 8.0% to 9.5% down to 8.3% to 9.3%. The low end went up 30 bps and the top end came down 20 bps, and the market read the second half of that sentence. On the numbers, with first-half organic growth of 5.7% against a $25,116M 2025 base, the full-year range requires 10.6% at the low end, roughly 11.5% at the midpoint and 12.5% at the high end for the second half, against a second half of 2025 that itself grew 10.3% organic.

An analyst put the midpoint requirement at about 11% on the call and management did not flinch.

"So that 11%, we feel very, very confident. Delivering. Other otherwise, we would not have raised the lower end of our sales guidance."
— Kevin A. Lobo, Chair and CEO

Assessment: Management chose to make the raised floor, not the lowered ceiling, the signal, and they are entitled to: cutting the top end of a range while raising the bottom is what a team does when it has resolved downside uncertainty and has not yet resolved upside. The uncomfortable fact is that the second-half requirement went up rather than down after this print. In April the balance-of-year requirement was 9.7% to 11.7%; the second quarter delivered 9.0%, below the midpoint of that path, and the shortfall rolled forward.

4. Decomposing the Second Half Into Run-Rate and Catch-Up

The eleven percent number is intimidating in isolation and much less so once it is separated into the part that is the ordinary business and the part that is the cyber catch-up. Applying the second quarter's 9.0% organic rate to the $13,228M second half of 2025 produces $1,190M of growth dollars. The guide requires $1,402M at the low end, $1,527M at the midpoint and $1,653M at the high end.

Those cells are the above-run-rate revenue the guide embeds, which is to say the catch-up. Set against our April estimate of the first-quarter hole at $330M to $420M, the guide midpoint on the as-reported run-rate assumes essentially the low end of that hole returns in the second half. Adjust for the vascular disruption and it assumes materially less.

Assessment: This is the analytical heart of the print and it cuts the bull's way. The second half does not require the base business to accelerate to a rate Stryker has never sustained. It requires the base business to hold roughly its current rate and for roughly half to all of an already-identified, already-ordered backlog to physically ship. That is a manufacturing scheduling question, not a demand question, and manufacturing scheduling is the one variable management can actually see.

5. The Capacity Question, Finally Asked

In April we flagged that nobody had asked whether Stryker has the production slots to build both the deferred first-quarter book and a normal second half out of nine months of capacity. This quarter it was asked directly and repeatedly, and it was the most pointed line of questioning on the call.

"The orders are already there. So demand is not the problem. As it relates to capital equipment. it is really just being able to fulfill those demands and could we have an issue here or there? it is always possible. We think we have accounted for that. In the guidance that we have provided."
— Kevin A. Lobo, Chair and CEO

The specifics management gave were that the plants have run consistently since April 1, that shifts have been added, that the products in question are established rather than new, and that the guidance was set at a level the team is comfortable delivering rather than at the top of what is theoretically producible.

Assessment: The answer is directionally reassuring and structurally unverifiable, which is the same shape as most manufacturing-capacity answers. What raises its value above boilerplate is the specific claim that these are known products on known lines with added shifts, rather than new product ramps. That is the difference between a scheduling problem and a learning-curve problem, and it is the reason we are willing to underwrite the second half at all.

6. The Recovery Buckets: Revenue Recognition Is Done, and It Was Small

In April management described three recovery buckets: deferred revenue recognition on consigned orthopaedic procedures already performed, rescheduled procedures, and make-to-order MedSurg capital. Our April read was that the first bucket was the easy half and that a second quarter which merely looked fine would not be confirmation. Management has now closed that bucket.

"But the way to probably to think about it is the rev rec piece is done. And you really start to see the capital components of that and the rescheduling of procedures More so in Q3, Q4."
— Preston Wells, CFO

Asked to size it, management said it was a small piece of the quarter and declined to quantify. That is a meaningful disclosure in both directions: the easy money is spent, and the second quarter's 9.0% was therefore mostly the real business rather than paperwork.

Assessment: This is more constructive than it first reads. If the revenue-recognition catch-up was small, then the 9.0% organic result is a cleaner read on the underlying franchise than we expected going in, and the entire remaining catch-up, the harder two-thirds, is still ahead in the order book rather than already consumed. The corollary is that October carries the full weight of the test, exactly as we said in April.

7. Peripheral Vascular: Year Two of Inari Execution Problems

The vascular disruption is the only genuinely new negative in the quarter, and it is worth separating from the cyber narrative entirely because it has nothing to do with it. A single plant that manufactures most of the Inari product line failed, creating a backorder that management describes as pretty elevated and expects to work down to a manageable level by the end of the third quarter. Management would not describe the failure.

"The supply disruption, I am not going to get into the details of what it was, but let's just say it did cause a significant backorder specific to 1 plant in the Inari business."
— Kevin A. Lobo, Chair and CEO

The CEO framed it, credibly, as the ordinary friction of moving an acquired business onto Stryker systems, citing the same experience with Sage and Mako. He was also candid that the lost revenue is genuinely lost rather than deferred, because these are emergent procedures that cannot wait, and that the company ran an allocation process protecting its highest-volume accounts at the expense of smaller ones.

"Our problems are internal to us. We will get those problems resolved. We will get back to the double digit growth, as we rectify our supply chain challenges."
— Kevin A. Lobo, Chair and CEO

Assessment: The candour is worth something and the revenue at stake is not large. The pattern is what concerns us. Inari's first year under Stryker was consumed by sales-force turnover and non-compete disputes, which management characterized at the time as transitional. The second year opens with a manufacturing failure and an allocation process that handed smaller accounts to competitors in a market where the seminal clinical trial reads out next year. For a thesis pillar built on Stryker's ability to improve acquired assets, this is the second consecutive year of evidence pointing the other way.

8. Capital Demand and the Order Book

The capital environment is the load-bearing assumption of the second half, and management was unusually specific about it. The backlog is elevated exiting the quarter, orders were strong, and there have been no cancellations.

"As we mentioned earlier, we have an elevated backlog. As we exit the quarter. We have seen zero cancellations in our books"
— Kevin A. Lobo, Chair and CEO

Against a backdrop of widely reported hospital capital caution, management also rejected the softness narrative on procedures, noting that the vast majority of Stryker's portfolio supports high-acuity, medically necessary and emergent care rather than discretionary volume, and that they have not observed meaningful changes in volume trends.

Assessment: A zero-cancellation claim on an elevated backlog is the most checkable forward-looking statement management made, and it will be checkable in October. If the second half disappoints and cancellations turn out to have been the reason, this quote is where the credibility damage will be measured. We take it at face value for now because the order book is the one dataset management can see and we cannot, and because the same claim was made and subsequently validated in April.

9. Mako at Twenty, and RPS Goes Fully Commercial

Stryker delivered its best-ever second quarter for Mako installations in both the United States and internationally, with utilization across the installed base continuing to rise. That follows a best-ever first quarter achieved in eleven working weeks, which means the robotics franchise has now compounded through the outage and out the other side without a visible interruption. The platform passed 2.5 million procedures globally across 47 countries in its twentieth year.

Mako RPS, the handheld robotic system that opens the manual-instrument and ambulatory surgery center channel, moved from limited launch to full U.S. commercial launch during the quarter. Management is deliberately targeting competitive users first rather than converting existing Stryker surgeons.

"We were in limited launch for the second quarter, and the feedback has been really outstanding."
— Kevin A. Lobo, Chair and CEO

On the ambulatory shift, management put hips and knees at high-teens to nearly 20% of procedures performed in ambulatory surgery centers against roughly 5% before the pandemic, with the pace now limited by construction rather than by surgeon willingness.

Assessment: The robotics pillar is the least ambiguous part of the thesis and it strengthened again this quarter. RPS matters more than its near-term revenue because it addresses the subset of surgeons who will never adopt a full Mako system, which is the one structural ceiling on the installed-base flywheel. Targeting competitive accounts first is the right sequencing and also the slower one, so expect the revenue contribution to lag the strategic significance by a year.

10. Share Repurchases Return After Six Years

The genuinely new disclosure of the call was buried in the prepared remarks. Stryker will resume share repurchases this quarter, for the first time in roughly six years, with about $1B already board-authorized.

"Additionally, considering our elevated level of cash flow generation, and recent valuation compression across the medtech sector, we plan to resume share repurchases this quarter."
— Preston Wells, CFO

Pressed on sizing and on whether this signals a shift away from acquisitions, management was clear that M&A remains the first priority and that the buyback is a supplement funded by cash flow growth rather than a reallocation. The CEO was more direct about the trigger than the CFO.

"But given the sheer size of our cash flow, we can also start to do opportunistic share buybacks. And given where the price of stock is, we are going to start to do that."
— Kevin A. Lobo, Chair and CEO

Assessment: Two signals, and both are useful. The first is a valuation signal from the party with the best information, delivered without hedging. The second is a balance-sheet signal: a company that retired $1.0B of debt in the first quarter, closed an acquisition in the second and is now buying stock while calling M&A its top priority is telling you the leverage constraint is not binding. The earnings contribution is small, roughly a point of share count at current prices, but the information content is not.

11. The Margin Algorithm: Three Years Reaffirmed, One Year Unmentioned

Asked what drives the second-half margin and EPS cadence, the CFO reaffirmed the multi-year commitment without restating the current-year figure.

"So first of all, we are still committed to what we talked about last year, which is our 150 basis points over the course of 3 years. So that is still our commitment."
— Preston Wells, CFO

He then listed the moving parts working against it: cyber-related lost absorption and idle costs still to be recovered, remediation and stabilization spending running through the year, and input-cost pressure in oil and other raw materials, offset by the tariff refund. The roughly 50 bps of full-year adjusted operating margin expansion that the company described in April was not repeated on this call, and neither was the 70% to 80% free cash flow conversion target.

Assessment: The first half delivered 10 bps of adjusted operating margin expansion. For the year to land near 50 bps, the second half has to expand roughly 80 bps over a second half of 2025 that already ran at 28.1%. That is achievable at the volumes the guide implies and it is not free. The absence of both single-year figures from an otherwise detailed answer is not a walk-back, but it is the kind of omission that gets noticed twice if the October print is soft.

12. Reimbursement Noise on Large Joints

A proposed Medicare rule cutting physician reimbursement for large joint procedures by as much as 20% drew one question. Management treated it as a recurring seasonal event rather than a structural threat.

"the proposed rules are always, it is a sticker shock, but this has been going on ever since I have been at Stryker. For 15 years. See the proposed rules come out. They create noise, and then the normal course of everybody voicing their opinions and ends up getting to a reasonable place."
— Kevin A. Lobo, Chair and CEO

The more interesting part of the answer was the second-order effect: reimbursement pressure accelerates the shift of procedures to ambulatory surgery centers, which management characterized as a favourable outcome for Stryker because the company can compete across its whole portfolio in that setting rather than only in hips and knees.

Assessment: The dismissal is probably correct on the specific rule and the site-of-care argument is genuinely strategic rather than a deflection. Stryker sells the operating-room infrastructure, the instruments and the implants, so a procedure moving to an ambulatory setting increases rather than decreases its addressable content. We would not underwrite the reimbursement environment as a tailwind, but it is difficult to construct it as a thesis risk for this particular company.

Guidance & Outlook

Four further full-year items were given on the call rather than in the release, and two previously given items were not restated.

Implied second-half ramp. On organic sales, the guide requires 10.6% at the low end, roughly 11.5% at the midpoint and 12.5% at the high end, against 5.7% delivered in the first half and 10.3% organic in the second half of 2025. On earnings, first-half adjusted EPS of $6.29 leaves $8.66 to $8.81 for the second half, growth of 13.1% to 15.0% against the $7.66 second-half 2025 base. First-half adjusted EPS growth was 5.4%, so the earnings acceleration required is of the same order as the revenue acceleration and depends on the same volume leverage.

Street at: Consensus entering the print sat at $6.57B to $6.58B of revenue and $3.49 of adjusted EPS. The revenue line landed inside that range and the earnings line beat it by $0.20. Because the full-year midpoint moved only two and a half cents, the practical effect on the full-year Street number is close to nil: models that had already assumed a recovery-weighted second half were not moved, and models that had been carrying the guide midpoint as a ceiling now have management's own confirmation that it is a ceiling.

Guidance style: Stryker's long-standing pattern is to guide conservatively and raise. This quarter breaks that pattern in an informative way: after a $0.20 beat the company narrowed rather than raised, and lowered the top of the sales range while lifting the bottom. Management explained the mechanism honestly, which is that a tariff benefit arrived early and cyber costs arrive later. But a company that habitually creates headroom chose not to, twice in a row, and the second-half requirement is now the highest it has been at any point this year.

Analyst Q&A Highlights

Why a Twenty-Cent Beat Produced a Two-and-a-Half-Cent Raise

The opening question of the call did the most work, bundling the narrowing of the range, the lowered top end and the missing flow-through into a single ask. Management split the answer, addressing the guidance philosophy first and then the earnings arithmetic. The response conceded both halves of the problem without being pushed: part of the quarter's upside was a tariff refund rather than operating performance, and the remainder is spoken for by cyber costs still to be incurred.

Q: "EPS you had a really nice beat in the quarter versus what we were looking for. But it does not look like it is flowing through for the full year guidance, and I am curious why."
— Joanne Wuensch, Citi

A: "So from an EPS standpoint, when we look at the beat in the quarter, it is driven partially by the tariff refunds that are happening that happened in the quarter."
— Preston Wells, CFO

Assessment: The answer is honest and it is the reason for the selloff. Management is stating that full-year earnings power did not improve this quarter, and that anyone flowing the beat through was building a model management never endorsed. What was not answered, and was not asked as a follow-up, is how large either offsetting item is.

The Eleven Percent Second Half and What Underwrites It

The most-repeated topic of the call was the second-half organic requirement, and one questioner put the arithmetic on the record explicitly rather than asking management to supply it. The response did not dispute the number and instead redirected to the raised floor as the intended signal, on the argument that a management team lifting the bottom of a range is a management team that has resolved its downside case.

Q: "The organic growth needs to be about 11%, I think, in the second half. To reach the midpoint of the guidance. So is there any more color you can provide on what is driving your confidence to be able to recapture the lost sales to achieve that and, of course, offset the vascular supply issue you had."
— Larry Biegelsen, Wells Fargo

A: "So that 11%, we feel very, very confident. Delivering. Other otherwise, we would not have raised the lower end of our sales guidance."
— Kevin A. Lobo, Chair and CEO

Assessment: Management accepted the number rather than quibbling with it, which is the right way to answer and is more informative than a hedge would have been. The rhetorical move, treating the raised floor as proof of the midpoint, is not logically airtight, but the supporting evidence offered alongside it is concrete: capital orders in hand and visible production ramp rather than assumptions about the procedure market.

Separating Underlying Growth From Cyber Catch-Up

Investors need to know how much of the quarter's 9.0% was the ongoing business and how much was recovery, because the answer determines what the second half is actually being asked to do. Management declined to split it on the ground that the businesses vary too much, but volunteered two useful specifics in the process: that capital is where the significant second-half uptick sits, and that the bed franchise inside a double-digit-growth Medical business was a drag because production cannot be caught up quickly.

Q: "1 of the things we are all trying to figure out is what is underlying and what is catch up from first quarter"
— Robert Justin Marcus, JPMorgan

A: "So, really, I would say what you see really in the second quarter is primarily just the momentum of the underlying business primarily with a few other elements that are kind of maybe coming into play here and there throughout that business."
— Preston Wells, CFO

Assessment: A refusal to quantify that nonetheless answers the question. If the second quarter was primarily underlying momentum, then 9.0% is a cleaner read on the franchise than the market gave it credit for, and the entire catch-up remains ahead rather than partly consumed. That is a more constructive answer than the evasion it looks like at first hearing.

Whether the Factories Can Physically Build the Second Half

The capacity question we flagged as unasked in April was asked directly this time, and the questioner framed it as the thing investors are most worried about. The answer leaned on the distinction between a scheduling problem and a ramp problem: these are established products on established lines with shifts added, not new products climbing a learning curve, and the guidance was set at a level the team believes it can deliver rather than at the theoretical production ceiling.

Q: "are there any factors that potentially could impact your ability to make enough product? It seems like primarily in med surg. To be able to deliver a significant ramp in Q3 and Q4."
— Matthew Oliver O'Brien, Piper Sandler

A: "The orders are already there. So demand is not the problem. As it relates to capital equipment. it is really just being able to fulfill those demands and could we have an issue here or there? it is always possible. We think we have accounted for that. In the guidance that we have provided."
— Kevin A. Lobo, Chair and CEO

Assessment: This is the most consequential answer of the call after the flow-through exchange, and it is the one that moved us. Management explicitly acknowledged execution risk and claimed to have provisioned for it in the guide rather than dismissing it, which is a materially more credible posture than April's silence on the same subject.

Sizing the Vascular Disruption Management Would Not Volunteer

The pattern from April repeated: the only quantification of a negative came from a questioner, and management confirmed it rather than supplying it. Independent arithmetic reaches the same place. U.S. Vascular organic fell 6.7% on a $268M prior-year U.S. base, which against a company-rate counterfactual implies about $39M of lost revenue and about 65 bps of company organic growth, sitting squarely inside the range the question proposed.

Q: "How much of an organic drag was it? Our math says could have been 50 to 75 basis points. Is that sort of roughly the right ballpark as we think about the impact in the second quarter?"
— Matthew Blackman, TD Cowen

A: "You are in the ballpark. On the impact. The financial impact you stated was you are in the ballpark."
— Preston Wells, CFO

Assessment: Confirming a range someone else calculated is the minimum viable disclosure, and it is now the second consecutive quarter in which the only number attached to a problem originated outside the company. The confirmation does matter for the model: it means the clean second-quarter run-rate was closer to 9.6% than 9.0%, which in turn lowers the catch-up the second-half guide implicitly requires.

The Return of the Buyback and What It Signals About Capital Priorities

A questioner connected the depressed share price to the capital allocation framework and asked whether the bias had shifted. The answer preserved acquisitions as the stated first priority while making clear that the buyback is funded by cash flow growth rather than by a reallocation away from deals, and that its timing will be governed by deal flow and by the share price itself.

Q: "But curious given where the stock is, Kevin, and you guys just put up great numbers. Is there a bias towards share repo? I know you mentioned on the call. Maybe talk about the opportunity that you see you know, and what is the size that we could, think of from a share repo perspective?"
— Vijay Muniyappa Kumar, Evercore ISI

A: "In terms of size and of what that could look like, we do have already approved from a prior approval by the board about a billion dollars available for us. I am not saying that is what we are going to do, but that is what we have available."
— Preston Wells, CFO

Assessment: The careful answer came from the CFO and the revealing one came from the CEO later in the same exchange, who tied the decision directly to the share price without qualification. A first repurchase in six years, announced at a multiple two turns below where the stock traded eighteen months ago, is a valuation opinion from the best-informed holder of the stock.

The Second-Half Margin Cadence and What Sits Against It

One questioner probed the shape rather than the level, noting that Street models imply lower fourth-quarter earnings than the pattern would suggest and asking what accounts for it. The answer catalogued the offsetting forces without ranking or sizing them: recovery of cyber-related lost absorption and idle costs, ongoing remediation and stabilization spending, and raw material pressure including oil, against the tariff refund on the other side.

Q: "If I look at kind of how the Street is thinking about Q3 to Q4, what is it that is going to drive maybe lower EPS in fourth quarter, which is kind of what the Street is assuming to get to the guidance."
— Ryan Benjamin Zimmerman, BTIG

A: "So first of all, we are still committed to what we talked about last year, which is our 150 basis points over the course of 3 years. So that is still our commitment."
— Preston Wells, CFO

Assessment: The three-year commitment was reaffirmed and the current-year figure was not, in an answer whose entire subject was the current year. That is a small omission with a large tell embedded in it, and it is the single item we would most want clarified before the October print. The list of offsetting pressures was otherwise candid and complete.

What They're NOT Saying

1. The size of the tariff benefit inside adjusted results. Named three times as a driver of the beat and of gross margin expansion, quantified never. The company separately disclosed and excluded a $158M prior-year tariff reversal, so the machinery to disclose exists and was not used for the current-year benefit.
2. The size of the cyber remediation and idle-cost bill. Management identified manufacturing lost absorption and IT and research remediation costs as the specific items consuming the second-half benefit of the beat. No figure, no range, no split between the two.
3. What broke in the Inari plant. Declined outright. For a supply failure that cost roughly 65 bps of company growth, handed accounts to competitors and occurred in the second year of the company's most consequential recent acquisition, "I am not going to get into the details" is a thin answer, particularly on the question of whether it is structural or one-off.
4. The shape of the second half. Asked twice whether the catch-up is third-quarter or fourth-quarter weighted, management answered that it will be a steady cadence across both. In a year whose entire debate is timing, declining to shape the quarters removes the only checkpoint before October.
5. The full-year adjusted operating margin figure. The three-year commitment of 150 bps or more was reaffirmed. The roughly 50 bps of 2026 expansion described in April was not repeated, inside an answer devoted to 2026 margins.
6. Free cash flow conversion. The 70% to 80% full-year target given in April was not restated, despite an unusually strong cash quarter that would have made restating it easy and flattering.
7. The unexplained charges, now a running total. Structural optimization charges include $87M year to date for "termination of sales relationships in certain countries" against a $4M credit in the prior-year first half, of which $81M landed in the first quarter and has never been discussed. This quarter adds $70M of unlabelled "other charges," nearly six times the prior-year quarter. Neither has been raised in Q&A across two calls.
8. Anything about the cyber investigation. The incident was discussed only as a cost line. No update on the investigation, the threat actor, insurance recovery, litigation or regulatory exposure, and no question asked. Four months after an event the company told the SEC was material to operations, the silence is now mutual.

Market Reaction

• Pre-print setup: SYK closed at $348.04 on Thursday July 30, down 1.0% year to date against an S&P 500 up 8.7%, down 13.1% over the trailing twelve months, but up 10.5% over the trailing thirty days. The 52-week closing range entering the print was $282.58 to $400.57, so the stock had recovered 18.1% from its $294.73 post-first-quarter close and 23.2% from the bottom of that range.
• Next-day session: The release crossed after the close with the call at 4:30 p.m. ET. The stock gapped down 5.2% to open at $330.10 on Friday July 31, traded a range of $317.62 to $334.46, and closed at $325.70, down 6.4% or $22.34.
• Volume: 4.5M shares against a 2.6M thirty-day average, or 1.8 times normal.
• Index context: The S&P 500 rose 0.7% on the same session, leaving roughly 7.1 points of relative underperformance.

The shape of this session is the mirror image of the one after the first-quarter print, and the difference is diagnostic. In May the stock gapped down 0.6% and closed down 6.5%, which is the signature of a market reading the fine print over the course of a day. This time the damage was done at the open: a 5.2% gap that never traded back to the prior close, then a grind that closed nearer the low. That is a market that had both the release and the 4:30 p.m. call overnight and reached its conclusion before the opening bell.

The problem it reached is arithmetic rather than operational. A $0.20 beat that moves the full-year midpoint two and a half cents, alongside a sales range whose top end came down, tells a reader in thirty seconds that the year has not improved. The pre-print positioning made that expensive. The stock entered the print having risen 10.5% in thirty days, most of it a recovery from a 52-week low, which means the marginal holder had bought the recovery thesis recently and at a higher price than the holders who owned it through April. A cohort with a three-week cost basis is the most reflexive seller there is when the raise does not arrive.

Volume at 1.8 times the thirty-day average is notably lower than the 2.3 times that accompanied the May decline, and that gap is the most useful signal in the session. In May positions changed hands on a new closing low. This time the participation was ordinary. That combination, a violent price move on unexceptional volume, describes a repricing of expectations rather than a repricing of the business. The multiple went from 23.2 times the guide midpoint to 21.7 times, which is a give-back of the pre-print run rather than a de-rating below where the stock traded a month ago.

Street Perspective

Debate: Is the second-half guide a stretch or an arithmetic formality?

Bull view: The bull case on the Street is that the eleven percent headline is an illusion created by a distorted first-half base. The business is running at nine percent, the incremental requirement is a defined backlog of capital equipment with purchase orders attached and no cancellations, and management raised the floor of the range precisely because the downside case is now closed.

Bear view: The bear camp contends that the second half now needs a rate Stryker has hit exactly once in recent history, against a second half of 2025 that itself grew above ten percent organic, and that the company has already missed the balance-of-year path it set in April by delivering nine percent when the midpoint required nearly eleven. Every quarter of underperformance makes the remaining requirement steeper, and there are only two quarters left.

Our take: The bulls have the better of this, and the decomposition is why. Strip the run-rate out and the guide embeds $211M to $463M of above-trend revenue depending on where in the range you sit, against our estimate of a $330M to $420M first-quarter hole. The midpoint is therefore not a bet on acceleration; it is a bet that roughly the low end of an already-sized backlog physically ships in six months. The bears are right that the requirement rose rather than fell after this print, and that is a real mark against the April path. It is not the same thing as the requirement being unreachable.

Debate: Does the tariff-assisted beat mean 2026 earnings power is overstated?

Bull view: The optimistic reading is that the tariff benefit is a real cash item that reflects a genuinely improved trade environment, that management conservatively excluded the largest piece of it, and that the operating margin story survives without it because 110 of the 170 basis points of expansion came from expense leverage rather than gross margin. The company is being punished for disclosing an offset it did not have to volunteer.

Bear view: The skeptical reading is that an unsized benefit inside an adjusted number is exactly what management teams leave unsized when the number is large. The full-year guide barely moved after a substantial beat, which is management's own admission that the underlying year is unchanged, and the second half now has to expand operating margin roughly eighty basis points against input-cost pressure and a remediation bill neither of which has been quantified either.

Our take: We split this one. The bears are right that the disclosure gap is real and that it is the wrong gap to leave open: a company that itemizes a $158M prior-year reversal and leaves the current-year benefit as an adjective has made a choice. The bulls are right that the expense leverage is verifiable, repeatable and the larger part of the margin story. What settles it practically is that management already told us the answer to the question the debate is about. Full-year earnings power did not change this quarter. That is not a scandal; it is a fact investors should have priced before the print rather than after it.

Debate: Is the Inari supply failure an incident or a pattern?

Bull view: The bull framing is that integration friction is the normal cost of acquiring, that Stryker has been through exactly this with Sage and with Mako and emerged with better businesses each time, that the sales force is finally stable and hungry after a year of turmoil, and that a backorder resolved inside one quarter in a market whose seminal clinical trial reads out next year is a rounding error against the asset's option value.

Bear view: The bear camp contends that two consecutive years of self-inflicted disruption in the same acquisition is not friction, it is a capability question. Year one was sales-force turnover and non-compete disputes; year two is a plant that could not supply its own products, forcing an allocation process that handed smaller accounts to competitors in emergent procedures that do not wait. Management would not say what broke, which is what a company says when the answer is not reassuring.

Our take: The bears have the better of this one and it is the reason we are downgrading a thesis pillar rather than merely noting a bad quarter. The revenue is recoverable and the market opportunity is real. But the entire justification for the price paid was that Stryker's operating machine improves acquired assets faster than the seller could, and the evidence base for that claim is now two years of the opposite. This does not change the 2026 numbers. It changes what we are willing to underwrite about the next acquisition.

Model Update & Valuation Framework

Where our estimate sits and why. We move to approximately $14.90 of full-year adjusted EPS, five cents below the bottom of the guide, from a prior range of $14.65 to $14.90. The raise is arithmetic rather than a change of view: the first half banked $6.29 against our expectations, and the second-quarter operating expense leverage was better than we modelled. We remain below the guide because the second half has to absorb the vascular backorder, an unquantified cyber remediation bill, and the possibility that the tariff benefit that helped the second quarter does not repeat at the same magnitude. If the capital backlog ships as management describes, we are wrong by five to twenty cents and in the right direction.

Valuation. At the $325.70 reaction-day close the stock trades at 21.7 times the FY26 guide midpoint of $15.025, 21.9 times our own FY26 estimate of approximately $14.90, 19.4 times our FY27 estimate of approximately $16.80, and 23.9 times trailing 2025 adjusted EPS of $13.63. Entering the print it was 23.2 times the guide midpoint. At our April initiation, at a $294.73 close, it was 19.6 times.

Price target framework. We raise the twelve-month target to $370 from $365, anchored to 22 times our FY27 estimate of approximately $16.80. The multiple is unchanged and remains deliberately below the pre-2026 average, so the target continues to require the recovery to happen and the multiple to stop compressing rather than to re-rate. From the $325.70 close that is roughly 13.6% of price upside plus a dividend yield near 1.1%.

Downside case. If the second half runs at the current nine percent rate rather than the guided eleven and a half, full-year adjusted EPS lands near $14.60 and the stock likely retraces toward the high $290s, roughly where it traded before the pre-print run and near 20 times a disappointing year. That is approximately 9% below the close. The downside case has genuinely narrowed since April, because the first half is banked, the plants are running and the order book has been confirmed twice. The upside case has narrowed further, because the stock captured most of the recovery re-rating before the recovery was proved. The resulting risk and reward is roughly one and a half to one, against roughly two to one when we initiated.

Thesis Scorecard Post-Earnings

The pillars below are the standing thesis established at initiation, scored against what this quarter's print and call revealed. They are not re-derived.

Overall: The thesis is intact and modestly strengthened on the operating side. Four of the seven pillars improved their status or were confirmed outright, including the margin pillar we opened at risk. The two things that got worse are the second-half arithmetic, which stiffened because this quarter came in below the path April required, and the acquisition-execution pillar, which took genuine damage from a supply failure that had nothing to do with the cyber event. Neither changes the shape of 2026. Together they argue for less conviction at a higher price rather than a different conclusion.

Action: Hold the position, do not add here. Our April call was to buy the de-rating, and the de-rating has substantially reversed: the stock has returned 10.5% against a 4.0% index over three months and the multiple has recovered two turns while the thesis-critical evidence remains three months away. What we said in April still governs. The first honest read on the recovery is the October print, and it is now the read on the harder two-thirds of the catch-up with less valuation cushion underneath it. If the third quarter shows the capital backlog converting on schedule, this is an Outperform into a clean 2027. If it does not, the rating goes to Hold and the target goes with it.